No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALLT Allot
- 2.100
- +0.020+0.96%
Close Apr 18 16:00 ET
80.73MMarket Cap-1265P/E (TTM)
2.100High2.080Low6.09KVolume2.080Open2.080Pre Close12.75KTurnover0.03%Turnover RatioLossP/E (Static)38.44MShares3.34052wk High1.62P/B40.82MFloat Cap1.19052wk Low--Dividend TTM19.44MShs Float29.050Historical High--Div YieldTTM0.96%Amplitude1.190Historical Low2.091Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shareholders in Allot (NASDAQ:ALLT) Are in the Red If They Invested Three Years Ago
Allot Finance Chief to Leave in Mid-year
Allot: Leitman to Continue in His Position Through June 30 to Ensure Seamless Transition >ALLT
Allot: Leitman to Continue in His Position Through June 30 to Ensure Seamless Transition >ALLT
Allot Ltd Commenced Formal Search for New CFO After Ziv Leitman Disclosed Plans to Depart to Join A Startup,
Allot Ltd. (NASDAQ:ALLT, TASE: ALLT))))), a leading global provider of innovative network intelligence and security solutions for service providers and enterprises worldwide, today announced that its
Allot: Commenced Search for New CFO >ALLT
Allot: Commenced Search for New CFO >ALLT
Allot: Leitman Leaving to Become CFO at Startup in Different Field >ALLT
Allot: Leitman Leaving to Become CFO at Startup in Different Field >ALLT
Comments
Shareholders of Allot may be disgruntled due to the firm's poor recent performance and excessive CEO compensation. A review of executive pay could be on cards considering the sharp drop in EPS and investor loss over the past three years.
Here's Why It's Unlikely That Allot Ltd.'s (NASDAQ:ALLT) CEO Will See A Pay Rise This YearThe stock's low P/S ratio, likely due to investors' doubt on robust revenue growth prospects and current conditions like declining revenues, could keep the share price low unless top-line growth substantially improves.
Institutional buying
Top 4 why only 4? Because those are all that are buying
$Allot(ALLT.US$ buy in 7.82 sell 12.25 after 8.23 the gaps are 9.76, 10.40, 11.34, 11.84 12.08.
$Synchronoss Technologies(SNCR.US$ Buy in 1.59 sell 2.23.
$Puma Biotechnology(PBYI.US$ buy in 2.72 sell 6.48.
$Avalo Therapeutics(AVTX.US$ buy in .64. sell 1.76. Institutional investor has continued buying but the price may not have found bottom yet.
$Allot(ALLT.US$ buy in 7.82 sell 12.25 after 8.23 the gaps are 9.76, 10.40, 11.34, 11.84 12.08.
$Synchronoss Technologies(SNCR.US$ Buy in 1.59 sell 2.23.
$Puma Biotechnology(PBYI.US$ buy in 2.72 sell 6.48.
$Avalo Therapeutics(AVTX.US$ buy in .64. sell 1.76. Institutional investor has continued buying but the price may not have found bottom yet.
4
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg